References
- Prescription Drug Expenditures in 2001: Another Year of Escalating Costs, NIHCM Foundation, March, 29, 2002. Available at URL:, , www.nihcm.org.
- Lund VJ. Seasonal allergic rhinitis—a review of current therapy. Allergy 1996; 51: 5–7
- MICROMEDEX Healthcare Series: MICROMEDEX, Greenwood Village, Colorado, (vol. 113 expires 9/2002).
- Monroe EW. Chronic urticaria: review of nonsedating H1 antihistamines in treatment. J Am Acad Dermatol 1988; 19: 842–9
- Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999; 57: 31–47
- Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645–57
- Ballmer-Weber BK, Gex-Collet C, Wuthrich B. Inhibition of histamine or allergen-induced wheals by a single dose of acrivastine, Fexofenadine or cetirizine. J Investig Allergol Clin Immunol 1999; 9: 351–5
- Grant JA, Danielson L, Rihoux JP, et al. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54: 700–7
- Grant JA, Danielson L, Rihoux J, et al. A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine. Int Arch Allergy Immunol 1999; 118: 339–40
- Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of Fexofenadine, Loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200–6
- Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and Fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73–9
- Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of Fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33
- Lopez GA, Paz MD, Orea SM, et al. Efficacy and safety of Fexofenadine and cetirizine in the treatment of allergic rhinitis. Rev Alerg Mex 2001; 48: 168–72
- Prenner BM, Capano D, Harris AG. Efficacy and tolerability of Loratadine versus Fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000; 22: 760–9
- Terrien MH, Rahm F, Fellrath JM, et al. Comparison of the effects of Terfenadine with Fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999; 103: 1025–30
- Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by Fexofenadine hydrochloride 120 mg, Loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891–9
- Benedetto SR, Sloan AS, Duncan BS. Impact of interventions designed to increase market share and prescribing of Fexofenadine at CHSs. Am J Health Syst Pharm 2000; 57: 1778–85
- Brufsky JW, Ross-Degnan D, Calabrese D, et al. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization. Med Care 1998; 36: 321–32
- Lee J, Cummins G, Okamoto L. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis. Am J Manag Care 2001; 7: S103–12
- Liao E, Leahy M, Cummins G. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. Am J Manag Care 2001; 7: S459–68
- Schectman JM, Kanwal NK, Schroth WS, et al. The effect of an education and feedback intervention on group-model and network-model health maintenance organization physician prescribing behavior. Med Care 1995; 33: 139–44
- Schectman JM, Schroth WS, Elinsky EG, et al. The effect of education and drug samples on antihistamine prescribing costs in a CHS. CHS Pract 1996; 10: 119–22
- Prescription Drugs and Mass Media Advertising, 2000, NIHCM Foundation, November, 21, 2001. Available at URL:, , www.nihcm.org.